DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/5qfdf4/there_is_an) has announced the addition of Decision Resources, Inc's new report "There Is an Urgent Need for More Efficacious High-Grade Glioma Treatments, but Will the Current Therapeutic Pipeline Suffice?" to their offering.
There is a dearth of drug treatment options for high-grade glioma, especially for glioblastoma multiforme (GBM), which has a particularly poor prognosis. Meager advancements in prolonging the survival of patients have been made over the last decade, and there is a pressing need for efficacious therapies that are both safe and tolerable. The role of Roche's Avastin (bevacizumab) in GBM is still debated, and the results of ongoing pivotal studies are eagerly anticipated with the hope that they will enlighten us regarding this biological therapy. With mediocre enthusiasm surrounding the late-stage pipeline for high-grade glioma, considerable opportunity remains for drug developers.
Key Topics Covered:
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- Disease Overview
- Current Therapies
- Emerging Therapies
- Challenges and Market Opportunities for Glioma
- Bibliography
For more information visit http://www.researchandmarkets.com/research/5qfdf4/there_is_an
Source: Decision Resources, Inc